Alwawi Eihab A, Krulig Eliana, Gordon Kenneth B
NorthShore University HealthSystem, Feinberg School of Medicine, Stokie, Illinois 60077, USA.
Dermatol Ther. 2009 Sep-Oct;22(5):431-40. doi: 10.1111/j.1529-8019.2009.01259.x.
Psoriasis is a chronic inflammatory condition that often requires life-long treatment. Conventional therapies have not fully met the needs of psoriatic patients, because of limited efficacy, adverse effects with cumulative use, and patient inconvenience. In the past decade, biologic immunotherapies have become accepted treatments for psoriasis as a result of perceived efficacy and safety on the part of patients and practitioners. However, most data on these medications come from relatively limited short-term trials. In this review, we will focus on the available long-term data on the efficacy of the biologic agents. We will emphasize the strengths and weakness of the available data of the biologic agents that are Food and Drug Administration (FDA)-approved for the treatment of moderate to severe psoriasis (alefacept, efalizumab,* etanercept, infliximab, and adalimumab), with the inclusion of a newer agent currently under FDA evaluation (ustekinumab).
银屑病是一种慢性炎症性疾病，通常需要终身治疗。传统疗法由于疗效有限、长期使用产生的不良反应以及给患者带来不便等原因，尚未完全满足银屑病患者的需求。在过去十年中，生物免疫疗法因其在患者和从业者看来的疗效和安全性，已成为银屑病的公认治疗方法。然而，关于这些药物的大多数数据来自相对有限的短期试验。在本综述中，我们将重点关注生物制剂疗效方面现有的长期数据。我们将强调已获美国食品药品监督管理局（FDA）批准用于治疗中度至重度银屑病的生物制剂（阿法赛特、依法利珠单抗、* 依那西普、英夫利昔单抗和阿达木单抗）现有数据的优缺点，其中还包括一种目前正在接受FDA评估的新型药物（优特克单抗）。
